Related references
Note: Only part of the references are listed.PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer
Farrokh Dehdashti et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer
Joan Duch et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer
Shigeto Ueda et al.
BMC CANCER (2008)
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer:: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy
Ute E. Krainick-Strobel et al.
BMC CANCER (2008)
Clinicopathological and prognostic relevance of uptake level using F-18-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (F-18-FDG PET/CT) in primary breast cancer
Shigeto Ueda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2008)
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
Matthew J. Ellis et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial
Masafumi Kurosumi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2008)
Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03)
Hiroyuki Takei et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version)
Masafumi Kurosumi et al.
BREAST CANCER (2008)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
M. Kaufmann et al.
ANNALS OF ONCOLOGY (2007)
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Letrozole in the neoadjuvant setting: the P024 trial
Matthew J. Ellis et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography
Caroline Rousseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1
Shigeto Ueda et al.
CANCER SCIENCE (2006)
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Current concepts - Positron-emission tomography and assessment of cancer therapy
ME Juweid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer
M Dowsett et al.
CLINICAL CANCER RESEARCH (2006)
Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer
E. Jane Macaskill et al.
ONCOLOGIST (2006)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
IE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials
Y Tao et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2005)
Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation
H Tsuda et al.
CANCER SCIENCE (2005)
Concordance in judgments among c-erbB-2 (HER2/neu) overexpression detected by two immunohistochemical tests and gene amplification detected by Southern blot hybridization in breast carcinoma
H Tsuda et al.
PATHOLOGY INTERNATIONAL (2001)
Share Paper
